Advertisement

Lupus Nephritis: Pathogenesis, Course and Management

  • James E. Balow
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 252)

Abstract

Lupus nephritis contributes notably to the morbidity and mortality of systemic lupus erythematosus. Improved medical therapies have increased the median survival of patients with lupus to more than 15 years over the past several decades. Uremia was a rare cause of death in the era before steroids, anti-hypertensives and antibiotics. As longevity of patients with lupus improved in the second half of the twentieth century, renal disease became a key factor in the clinical expression and management of this disease. Today, renal involvement is expected in the majority of patients with systemic lupus erythematosus.

Keywords

Systemic Lupus Erythematosus Nephrotic Syndrome Lupus Nephritis Membranous Nephropathy Proliferative Lupus Nephritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adelman NE, Watling DL and McDevitt HO: Treatment of [NZB/NZW] Fl disease with anti-la monoclonal antibodies. J Exp Med 158:1350–1355, 1983PubMedCrossRefGoogle Scholar
  2. Appel GB, Cohen DJ, Pirani CL, Meitzer JI and Estes D: Long- term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 83:877–885, 1987PubMedCrossRefGoogle Scholar
  3. Appel GB, Silva FG, Pirani CL, Meitzer JI and Estes D: Renal involvement in systemic lupus erythematosus (SLE): a study of 56 patients emphasizing histologic classification. Medicine 57:371–410, 1978.PubMedCrossRefGoogle Scholar
  4. Austin HA III, Klippel JH, Balow JE, leRiche NGH, Steinberg AD, Plötz PH and Decker JL: Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614–619, 1986.PubMedCrossRefGoogle Scholar
  5. Austin HA III, Muenz LR, Joyce KM, Antonovych TT and Balow JE: Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 25:689–695, 1984.PubMedCrossRefGoogle Scholar
  6. Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Kullick ME, Klippel JH, Decker JL and Balow JE: Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 75:382–391, 1983.PubMedCrossRefGoogle Scholar
  7. Baldwin DS, Gluck MC, Lowenstein J and Gallo G: Lupus nephritis: clinical course as related to morphologic forms and their transitions. Am J Med 62:12–30, 1977.PubMedCrossRefGoogle Scholar
  8. Baldwin DS, Lowenstein J, Rothfield NF, Gallo G and McCluskey RT: The clinical course of the proliferative and membranous forms of lupus nephritis. Ann Intern Med 73:929–942, 1970PubMedGoogle Scholar
  9. Balow JE and Austin HA III: Renal disease in systemic lupus erythematosus. Rheumatic Dis Clin North Am 14:117–133, 1988Google Scholar
  10. Balow JE, Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Klippel JH, Steinberg AD, Plötz PH and Decker JL: The effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 311:491–495, 1984.PubMedCrossRefGoogle Scholar
  11. Balow JE, Austin HA III, Tsokos GC, Antonovych TT, Steinberg AD and Klippel JH: Lupus nephritis. Ann Intern Med 106:79- 94, 1987PubMedGoogle Scholar
  12. Border WA, Ward HJ, Kamil ES and Cohen AH: Induction of membranous nephropathy in rabbits by administration of an exogenous cationized antigen. Demonstration of a pathogenetic role for electrical charge. J Clin Invest 69:451–461, 1982.PubMedCrossRefGoogle Scholar
  13. Cade R, Spooner G, Schlein E, Pickering M, DeQuesada A, Holcomb A, Juncos L, Richard G, Shires D, Levin D, Hackett R, Free J, Hunt R and Fregly M: Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis. Nephron 10:37–56, 1973PubMedCrossRefGoogle Scholar
  14. Cameron JS, Boulton-Jones M, Robinson R and Ogg C: Treatment of lupus nephritis with cyclophosphamide. Lancet 2:846–849, 1970.PubMedGoogle Scholar
  15. Cameron JS, Turner DR, Ogg CS, Williams DG, Lessof MH, Chantler C and Leibowitz S: Systemic lupus with nephritis: a long- term study. Q J Med 48:1–24, 1979PubMedGoogle Scholar
  16. Carette S, Klippel JH, Decker JL, Austin HA III, Plötz PH, Steinberg AD and Balow JE: Controlled studies of oral immunosuppressive drugs in lupus nephritis: a long-term follow-up. Ann Intern Med 99:1–8, 1983.PubMedGoogle Scholar
  17. Cathcart ES, Idelson BA, Scheinberg MA and Couser WG: Beneficial effects of methylprednisolone pulse therapy in diffuse proliferative lupus nephritis. Lancet 1:163–166, 1976.PubMedCrossRefGoogle Scholar
  18. Cheigh JS, Stenzel KH, Rubin AL, Chami J and Sullivan JF: Systemic lupus erythematosus in patients with chronic renal failure. Am J Med 75:602–606, 1983.PubMedCrossRefGoogle Scholar
  19. Churg J and Sobin LH: Lupus nephritis. In, Renal Disease. Tokyo, Igaku-Shoin. 1982, pp 127–149.Google Scholar
  20. Correia P, Cameron JS, Lian JD, Hicks J, Ogg CS, Williams DG, Chantler C and Haycock DG: Why do patients with lupus nephritis die? Br Med J 290:126–131, 1985CrossRefGoogle Scholar
  21. Couser WG: Mechanisms of glomerular injury in immune-complexdisease. Kidney Int 28:569–583, 1985.PubMedCrossRefGoogle Scholar
  22. Decker JL, Klippel JH, Plötz PH and Steinberg AD: Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: Results at 28 months. Ann Intern Med 83:606–615, 1975.PubMedGoogle Scholar
  23. Decker JL, Steinberg AD, Reinertsen JL, Plötz PH, Balow JE and Klippel JH: Systemic lupus erythematosus: evolving concepts. Ann Intern Med 91:587–604, 1979PubMedGoogle Scholar
  24. Donadio JV Jr, Holley KE, Ferguson RH and Ilstrup DM: Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 299:1151–1155, 1978.PubMedCrossRefGoogle Scholar
  25. Donadio JV Jr, Holley KE, Wagoner RD, Ferguson RH and McDuffie FC: Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Ann Intern Med 77:829–835, 1972PubMedGoogle Scholar
  26. Drinkard JP, Stanley TM, Dornfield L, Austin RC, Barnett EV, Pearson CM, Vernier RL, Adams DA, Latta H and Gonick HC: Azathioprine and prednisone in the treatment of adults with lupus nephritis. Medicine 49:411–432, 1970PubMedCrossRefGoogle Scholar
  27. Dubois EL, Wierzchowiecki M, Cox MB and Weiner JM: Duration and death in systemic lupus erythematosus. JAMA 227:1399–1402, 1974PubMedCrossRefGoogle Scholar
  28. Ebling J and Hahn BH: Restricted subpopulations of DNA antibodies in kidneys of mice with systemic lupus erythematosus: comparison of antibodies in serum and renal eluates. Arthritis Rheum 23: 392–403, 1980.PubMedCrossRefGoogle Scholar
  29. Feldman MD, Huston DP, Karsh J, Balow JE, Klima E and Steinberg AD: Correlation of serum IgG, IgM, and anti-native-DNA antibodies with renal and clinical indexes of activity in systemic lupus erythematosus. J Rheumatol 9:52–58, 1982PubMedGoogle Scholar
  30. Feutren G, Querin S, Tron F, Noel LH, Chatenoud L, Lesavre P and Bach JF: The effects of cyclosporine in patients with systemic lupus. Transplant Proc 18:643–644, 1986.Google Scholar
  31. Fries JF, Sharp GC, McDevitt HO and Holman HR: Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis. Arthritis Rheum 16:154–162, 1973PubMedCrossRefGoogle Scholar
  32. Garin EH, Donnelly WH, Shulman ST, Fernandez R, Finton G, Williams RL and Richard GA: The significance of serial measurements of serum complement C3 and C4 components and DNA binding capacity in patients with lupus nephritis. Clin Nephrol 12:148–155, 1979PubMedGoogle Scholar
  33. Gauthier VJ, Mannik M and Striker GE: Effect of cationized antibodies in preformed immune complexes on deposition and persistence in renal glomeruli. J Exp Med 156:766–777, 1982.PubMedCrossRefGoogle Scholar
  34. Ginzler EM, Diamond HS, Weiner M, Schlesinger M, Fries JF, Wasner C, Medsger TA, Ziegler G, Klippel JH, Hadler NM, Albert DA, Hess EV, Spencer-Green G, Grayzel A, Worth D, Hahn BH and Barnett EV: A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum 25:601–611, 1982PubMedCrossRefGoogle Scholar
  35. Hahn BH, Kantor OS and Osterland CK: Azathioprine plus prednisone compared to prednisone alone in the treatment of systemic lupus erythematosus: reports of a prospective controlled trial in 24 patients. Ann Intern Med 83:597- 605, 1975PubMedGoogle Scholar
  36. Hayslett JP, Kashgarian M, Cook CD and Spargo BH: The effect of azathioprine on lupus glomerulonephritis. Medicine 51:393- 412, 1972.PubMedCrossRefGoogle Scholar
  37. Isenberg DA, Snaith ML, Morrow WJ, Al-Khader AA, Cohen SL, Fisher C and Mowbray J: Cyclosporin A for the treatment of systemic lupus erythematosus. Int J Immunopharmacol 3:163- 169, 1981PubMedCrossRefGoogle Scholar
  38. Izui S, Lambert PH and Miescher PA: In vitro demonstration of a particular affinity of glomerular basement membrane and collagen for DNA: a possible basis for a local formation of DNA-anti-DNA complexes in systemic lupus erythematosus. J Exp Med 145:1115–1130, 1977.PubMedCrossRefGoogle Scholar
  39. Jacob CO and McDevitt HO: Tumour necrosis factor-alpha in murine autoimmune lupus nephritis. Nature 331:356–358, 1988PubMedCrossRefGoogle Scholar
  40. Jarrett MP, Santhanam S and Del Greco F: The clinical course of end-stage renal disease in systemic lupus erythematosus.Arch Intern Med 143:1353–1356, 1983PubMedCrossRefGoogle Scholar
  41. Klippel JH: Morbidity and mortality, pp 89–92. In: Balow JE, moderator. Lupus nephritis. Ann Intern Med 106:79–94, 1987Google Scholar
  42. Klippel JH, Austin HA III, Balow JE, leRiche NG, Steinberg AD, Plotz PH and Decker JL: Studies of immunosuppressive drugs in the treatment of lupus nephritis. Rheum Dis Clin North Am 13:47–56, 1987PubMedGoogle Scholar
  43. Koffler D, Agnello V, Carr I and Kunkel HG: Variable patterns of immunoglobulin and complement deposition in the kidneys of patients with systemic lupus erythematosus. Am J Pathol 56:305–319, 1969.PubMedGoogle Scholar
  44. Kramer P, Broyer M, Brunner FP, Brynger H, Donckerwolcke RA, Jacobs C, Selwood NH and Wing AJ: Combined report on regular dialysis and transplantation in Europe. XII. Proc Eur Dial Transplant Assoc 19:29–31, 1982Google Scholar
  45. Lewis E and Lachin J: Primary outcomes in the controlled trial of plasmapheresis therapy (PPT) in severe lupus nephritis (Abstract). Kidney Int 31:208. 1987.CrossRefGoogle Scholar
  46. Madaio MP, Salant DJ, Cohen AJ, Adler S and Couser WG: Comparative study of in situ immune deposit formation in active and passive Heymann nephritis. Kidney Int 23:498- 505, 1983.Google Scholar
  47. Michael AF, Keane WF, Raij L, Vernier RL and Mauer SM: The glomerular mesangium. Kidney Int 17:141–154, 1980.PubMedCrossRefGoogle Scholar
  48. Morel-Maroger L, Mery JP, Droz D, Godin M, Verroust P, Kourilsky O and Richet G: The course of lupus nephritis: contribution of serial renal biopsies. Adv Nephrol 6:79- 118, 1976Google Scholar
  49. Muehrcke RC, Kark RM, Pirani CL and Pollak VE: Lupus nephritis: a clinical and pathologic study based on renal biopsies. Medicine 36:1–145, 1957PubMedGoogle Scholar
  50. Palestine AG, Austin HA III, Balow JE, Antonovych TT, Sabnis SG, Preuss HG and Nussenblatt RB: Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 314:1293–1298, 1986PubMedCrossRefGoogle Scholar
  51. Pillemer S, Austin HA III, Tsokos GC and Balow JE: Lupus nephritis: association between serology and renal biopsy measures. J Rheumatol 15:284–288, 1988PubMedGoogle Scholar
  52. Platt JL, Burke BA, Fish AJ, Kim Y and Michael AF: Systemic lupus erythematosus in the first two decades of life. Am J Kidney Dis 2:212–222, 1982PubMedGoogle Scholar
  53. Pollak VE, Pirani CL and Kark RM: Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis. J Lab Clin Med 57:495–511, 1961.PubMedGoogle Scholar
  54. Pollak VE, Pirani CL and Schwartz FD: The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med 63:537–550, 1964PubMedGoogle Scholar
  55. Ponticelli C, Zucchelli P, Moroni G, Cagnoli L, Banfi G and Pascuali S: Long-term prognosis of diffuse lupus nephritis. Clin Nephrol 28:263–271, 1987PubMedGoogle Scholar
  56. Shemesh O, Golbetz H, Kriss JP and Myers BD: Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 28:830–838, 1985PubMedCrossRefGoogle Scholar
  57. Steinberg AD and Decker JL: A double-blind controlled trial comparing cyclophosphaanide, azathioprine and placebo in the treatment of lupus glomerulonephritis. Arthritis Rheum 17:923–937, 1974.PubMedCrossRefGoogle Scholar
  58. Stow JL, Sawada H and Farquhar MG: Basement membrane heparin sulfate proteoglycans are concentrated in the laminae rarae and in podocytes of the rat renal glomerulus. Proc Natl Acad Sci (USA) 82:3296–3300, 1985.CrossRefGoogle Scholar
  59. Strober S, Farinas MC, Field EH, Solovera JJ, Kiberd BA, Myers BD and Hoppe RT: Lupus nephritis after total lymphoid irradiation: persistent improvement and reduction of steroid therapy. Ann Intern Med 107:689–690, 1987PubMedGoogle Scholar
  60. Wallace DJ, Podell TE, Weiner JM, Cox MB, Klinenberg JR, Forouzesh S and Dubois EL: Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980. Am J Med 72:209–220, 1982PubMedCrossRefGoogle Scholar
  61. Wallace DJ, Podell TE, Weiner JM, Klinenberg JR, Forouzesh S and Dubois EL: Systemic lupus erythematosus--survival patterns. JAMA 245:934–938, 1981PubMedCrossRefGoogle Scholar
  62. Wei N, Klippel JH, Huston DP, Hall RP, Lawley TJ, Balow JE, Steinberg AD and Decker JL: Randomized trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1:17–22, 1983PubMedCrossRefGoogle Scholar
  63. Wofsy D and Seamon WE: Reversal of advanced murine lupus in NZB/NZW Fl mice by treatment with monoclonal antibody to L3T4. J Immunol 138:3247–3253, 1987PubMedGoogle Scholar
  64. Yeung CK, Wong KL, Wong WS, Ng MT, Chan KW and Ng WL: Crescentic lupus glomerulonephritis. Clin Nephrol 21:251- 258, 1984PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • James E. Balow
    • 1
  1. 1.Kidney Disease SectionNational Institutes of HealthBethesdaUSA

Personalised recommendations